La catena delle opzioni mostra i dati chiave delle opzioni azionarie di AltEnergy Acquisition a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per AltEnergy Acquisition..

AltEnergy Acquisition (OTC:AEAE) Azioni, Catena delle Opzioni

AltEnergy Acquisition Corp is a blank check company.

ALTENERGY ACQ CORP A by AltEnergy Acquisition Corp.

AltEnergy Acquisition Corp

AltEnergy Acquisition Corp Units (1 Ord Class A & 1/2 War)

AltEnergy Acquisition Corp Warrants (29/10/2026)

Needham analyst Gil Blum reiterates Mereo BioPharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) with a Buy and maintains $7 price target.

News

Price Target

Reiteration

Analyst Ratings

MREO

Needham Reiterates Buy on Mereo BioPharma Group, Maintains $7 Price Target

Jefferies analyst David Katz downgrades Xenia Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XHR#NYSE">XHR</a>) from Buy to Hold and lowers the price target from $18 to $10.

Downgrades

Jefferies Downgrades Xenia Hotels & Resorts to Hold, Lowers Price Target to $10

Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) with a Buy and maintains $41 price target.

RNAC

Needham Reiterates Buy on Cartesian Therapeutics, Maintains $41 Price Target

NEW YORK, April 9, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4399927-1&amp;h=3388766128&amp;u=http%3A%2F%2Fwww.imux.com%2F&amp;a=Immunic%2C+Inc.">Immunic, Inc.</a> ("Immunic" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing of a registered direct offering of 5,666,667 shares of its common stock at the market under Nasdaq rules at a price of $0.90 per share, led by Aberdeen Investments. All securities in the offering are being sold by Immunic.
The gross proceeds from the offering are expected to be approximately $5.1 million before deducting commissions and offering expenses. The offering is expected to close on or about April 10, 2025, subject to the satisfaction of customary closing conditions.
The Company intends to use the net proceeds received from the proposed offering to&nbsp;fund&nbsp;its&nbsp;clinical trials&nbsp;and&nbsp;operations&nbsp;and&nbsp;for&nbsp;other general corporate purposes.
Titan Partners Group, a division of American Capital Partners, is acting as the sole placement agent&nbsp;for the offering.

Offerings

IMUX

Immunic, Announces Pricing Of $5.1M Registered Direct Offering At $0.90 Per Share Led by Aberdeen Investments

Jefferies analyst David Katz downgrades Park Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PK#NYSE">PK</a>) from Buy to Hold and lowers the price target from $19 to $10.

Jefferies Downgrades Park Hotels & Resorts to Hold, Lowers Price Target to $10

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

LMFA

LM Funding America Mar. Net Bitcoin Mined 8.7

Needham analyst Joseph Stringer reiterates Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) with a Buy and maintains $22 price target.

STOK

Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Seaport Global analyst David Joyce upgraded the rating for Sirius XM Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) from Neutral to Buy and announced a $27 price target. Sirius XM shares closed at $19.34 on Tuesday. <a href="https://www.benzinga.com/quote/siri/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Asad Haider upgraded Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) from Neutral to Buy and raised the price target from $157 to $172. Johnson &amp; Johnson shares closed at $150.00 on Tuesday. <a href="https://www.benzinga.com/quote/jnj/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Korinne Wolfmeyer upgraded the rating for Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) from Neutral to Overweight but lowered the price target from $38 to $35. Bath &amp; Body Works shares closed at $25.51 on Tuesday. <a href="https://www.benzinga.com/quote/bbwi/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Edison Lee upgraded Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) from Underperform to Hold but lowered the price target from $202.33 to $167.88. Apple shares closed at $172.42 on Tuesday. <a href="https://www.benzinga.com/quote/aapl/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Andy Barish upgraded the rating for Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) from Underperform to Hold and maintained the price target of $76. Starbucks shares closed at $79.69 on Tuesday.  <a href="https://www.benzinga.com/quote/sbux/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AAPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="601" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09080916/image-50-1024x601.png" alt="" class="wp-image-863674" style="width:596px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09080916/image-50-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09080916/image-50-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09080916/image-50-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09080916/image-50.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44684755/top-3-industrials-stocks-you-may-want-to-dump-this-month">Top 3 Industrials Stocks You May Want To Dump This Month</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

Trading Ideas

AAPL

BBWI

SBUX

SIRI

This Apple Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday

Monster Beverage Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) ("Monster" or the "Company") today issued the following statement in response to a report issued on April 8, 2025 by a short-selling firm, Spruce Point Capital Management, containing false and misleading characterizations about the Company's business from&nbsp;non-credible sources.
Rodney Sacks and Hilton Schlosberg, Chairman and Vice Chairman, respectively, and Co-Chief Executive Officers of the Company, jointly stated: "We have always prided ourselves on having and continue to have a strong reputation for ethical operations and transparent reporting, and these principles remain critically important to all of us at Monster. The document released by a self-interested activist short seller is filled with and based on inaccuracies and aspersions that appear to be designed to distort the Company's record and share price for its own gain. The Company's management remains focused on the business with the ongoing objective of creating long-term value for our stakeholders and investors.
"The Company's consolidated financial statements and other financial information filed with the Securities Exchange Commission ("SEC") have historically been and continue to be fairly stated in all material respects, presented in accordance with generally accepted accounting principles and are governed by SEC rules and regulations."
The Board of Directors of the Company (the "Board") affirmed its confidence in the Company's management and strategic direction. Lead Independent Director, Mark Vidergauz, stated: "On behalf of the entire Board, we stand in support of the management team and believe that the Company remains well-positioned for long-term success."
The Company does not believe the report issued by Spruce Point Capital Management has any credibility and accordingly does not intend to comment further on the report.

Short Sellers

MNST

Monster Beverage Responds To Report By Short Seller Containing Inaccurate And Misleading Statements; Says "The Company Does Not Believe The Report Issued By Spruce Point Capital Management Has Any Credibility And Accordingly Does Not Intend To Comment Further On The Report"

Juniper's Mist AI-Native Networking Platform uses Google's Cloud WAN solution to help accelerate new branch deployments and optimize wired, wireless and WAN experiences
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.juniper.net%2F&amp;esheet=54235952&amp;newsitemid=20250409019929&amp;lan=en-US&amp;anchor=Juniper+Networks&amp;index=1&amp;md5=be7316cddb7dd8f4bba50078f47358f5">Juniper Networks</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>), a leader in secure, AI-Native Networking, announced its collaboration with Google Cloud to accelerate new enterprise campus and branch deployments and optimize user experiences. With just a few clicks in the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcloud.google.com%2Fmarketplace&amp;esheet=54235952&amp;newsitemid=20250409019929&amp;lan=en-US&amp;anchor=Google+Cloud+Marketplace&amp;index=2&amp;md5=5696192d9eec97f194e94b8bdc130eb8">Google Cloud Marketplace</a>, customers can subscribe to Google's Cloud WAN solution alongside Juniper Mist wired, wireless, NAC, firewalls and secure SD-WAN solutions. Unveiled today at Google Cloud Next 25, the solution is designed to simply, securely and reliably connect users to critical applications and AI workloads whether on the internet, across clouds or within data centers.
"At Google Cloud, we're committed to providing our customers with the most advanced and innovative networking solutions. Our expanded collaboration with Juniper Networks and the integration of its AI-native networking capabilities with Google's Cloud WAN represent a significant step forward," said Muninder Singh Sambi, VP/GM, Networking, Google Cloud. "By combining the power of Google Cloud's global infrastructure with Juniper's expertise in AI for networking, we're empowering enterprises to build more agile, secure and automated networks that can meet the demands of today's dynamic business environment."

Contracts

GOOGL

JNPR

Juniper Networks Enters Collaboration With Google Cloud To Accelerate New Enterprise Campus And Branch Deployments And Optimize User Experiences

SPAI

Safe Pro Group's Airborne Response Drone Services Subsidiary Receives Order Under Multi-Year Agreement With A Florida Electric Utilities Co.

Needham analyst Joseph Stringer reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $320 price target.

ALNY

Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target

Piper Sandler analyst Paul Newsome maintains Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) with a Overweight and lowers the price target from $132 to $122.

GSHD

Piper Sandler Maintains Overweight on Goosehead Insurance, Lowers Price Target to $122

Breakdown in board governance enabled the pursuit of a strategy that has not delivered for shareholders
Goff supports Elliott's engagement with Phillips 66 to maximize long-term value for all shareholders
Elliott's nominees will provide an infusion of independence and expertise in the Phillips 66 boardroom and ensure management is held to account

Management

Energy Industry Veteran Gregory J. Goff Releases Letter To Fellow Phillips 66 Shareholders; Supports Elliott's Engagement With Phillips 66 To Maximize Long-Term Value For All Shareholders

Oracle Database@Google Cloud is planned to be available through Oracle and Google Cloud partners for the first time
Oracle Base Database Service is coming soon in limited preview
Oracle Exadata X11M support and Oracle Interconnect for Google Cloud support for Oracle U.S. Government Cloud now available
AUSTIN, Texas and SUNNYVALE, Calif., April 9, 2025 /PRNewswire/ --&nbsp;Oracle and Google Cloud today announced plans for an industry-first partner program and the planned availability of Oracle Base Database Service on <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4401661-1&amp;h=2435018739&amp;u=https%3A%2F%2Fwww.oracle.com%2Fcloud%2Fgoogle%2Foracle-database-at-google-cloud%2F&amp;a=Oracle+Database%40Google+Cloud">Oracle Database@Google Cloud</a>, as well as expanded capabilities and additional regions. The new partner program is designed to enable Oracle and Google Cloud partners to offer Oracle Database@Google Cloud to their customers. In addition, Oracle Database@Google Cloud now supports Oracle Exadata X11M, and for Oracle U.S. Government Cloud customers, Oracle Interconnect for Google Cloud is available. Finally, 11 new regions are planned within the next 12 months to help meet growing customer demand for Oracle Database@Google Cloud.

ORCL

Oracle And Google Cloud Enters Industry-First Partner Program And Debut Powerful New Capabilities For Oracle Database @Google Cloud

Dividends

Tanger Declares Increased Dividend From $1.10 To $1.17 Per Share On Annualized Basis

FWRD

Forward Air Estimates Q1 Consolidated EBITDA $54M-$59M; Estimates That Between 10%-15% Of 2024 Revenues Would Have Been Impacted By Recently Announced Tariffs

NVEE

NV5 Wins $15M California Transportation Infrastructure Contract

Jefferies analyst David Katz downgrades Host Hotels &amp; Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HST#NASDAQ">HST</a>) from Buy to Hold and lowers the price target from $20 to $14.

Jefferies Downgrades Host Hotels & Resorts to Hold, Lowers Price Target to $14

CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 Billion Anxiety Market Worldwide
Non-Dilutive Funding Expands Pipeline and Further Validates Cingulate's Proprietary Precision Timed Release&#x2122; Drug Delivery Technology
CTx-2103 has the Potential to Reduce Use of Benzodiazepine's and Associated Withdrawal and Dependency Issues
KANSAS CITY, Kan., April 09, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=5_ftL4fAcSf9HLF8sW9s7BkANz0F4gxnFtdH7F863uK9hUbXlQ0G5VaFnFzQv_Zl0675i8BWY28VaCDYxfCRTzQcZuFA5wpg3nIgqcgaJy3SIDcZEBlQud3YRQpJeS6OxpoRm0WzGKzWUtoBRXM9CPFUO-ms_dTpW4DkYUG0jfjD_T3SBhCglz963X8YWLg-1nLyQvwBgteUQFJSHjWSvp-_UYQ2Mt2g-u4CJPsNtbtEL7TQHeERj8Fcgk1af-W3hliBqlb7PpWrLPORYjERJXlCMA8mXztm55EdVe4OH2fUFQJSp2heAFAbbsL2_FUR2k2WFp0ODP_U5bkaCDhR3ARkrbtPYMs8yeZIAYYc0WDMDr8t2JsufjEP2HWdayY3JGWZoeQc3jclFCI42khElbe-lB7wfUC4K8dq_YK82NIBboSb3LY03qkLEMOaa01yad7yZ7vF6ID21YMTxZ-r7MJCPTh3fqu2KgvwakWh-I_5rb7WbDPH2tHkzR1hyp6Ybz9XyW0GvrOqFIDyhsZBkA3xRJBqIuoCREs6gejinbhA3KuQM5pVtyuLN1oSNYfh73KRS04o0T_ms--GxtxXZWibM77tEow6dPxwnEm9RsNGNjLNz52TdVY5f6GKO_V9GV_XOiEXFAMQm5d5zreSMTsPKr15zi2Cs2-uViCu9zM=">Cingulate Inc.</a>&nbsp;(NASDAQ:<a href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>), a biopharmaceutical company utilizing its proprietary Precision Timed Release&#x2122; (PTR&#x2122;) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has received a $3 million grant to accelerate the development of CTx-2103 (buspirone) for the treatment of anxiety. CTx-2103 has the potential to be the first, once-daily formulation of buspirone, one of the most widely prescribed agents in the $5.5 billion U.S. anxiety market ($11.6 billion global).
The grant will be made in three tranches of $1 million each, the first tranche to be paid on May 1st , and the two subsequent tranches payable based on specified product development milestones. The foundation will receive a future royalty contingent on the commercialization of CTx-2103, beginning six months after the after the first commercial sale of CTx-2103, payable at $500,000 per quarter, with a maximum cumulative royalty of $3.5 million.

Biotech

General

CING

Cingulate Receives $3M Grant From Private Foundation To Accelerate Development Of Anxiety Asset CTx-2103; Beginning 6-Months After The After The First Commercial Sale Of CTx-2103, Payable At $500K Per Quarter, With A Maximum Cumulative Royalty Of $3.5M

Comments

AltEnergy Acquisition

AltEnergy Acquisition (AEAE) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO